The National Institute for Health Research (NIHR) HTA program, which undertakes independent HTA in the UK, also recognizes the role of patients and public. They have taken a decision to actively involve patients in their work program. They state that: «HTA research must address the questions that are important to those who use NHS services, and to ensure that it does this the HTA program actively involves members of the public throughout the research process» [5] . There is evidence that involvement is also considered important across the HTA field. Over half of the members of the International Network of Agencies for Health Technology Assessment (INAHTA) who responded when surveyed in 2005, said they involve consumers in their HTA work. Further, 83% said that they intended to involve them in the future [6] . Bridges and Jones suggest that patients are the most important stakeholder amongst many in HTA [7] . However, there remains concern that patients' perspective are rarely included, perhaps because they are seen as anecdotal, biased views [3] .
HOW CAN YOU INVOLVE THE PUBLIC AND PATIENTS IN HTA?
The options for involvement are many and varied, and that provides a menu of options for those undertaking HTA to develop an approach that works in their specific context. Facey et al. highlight that there are a number of research approaches [3] : -systematic reviews of qualitative research; -primary research including:
-qualitative methods such as individual in-depth interviews and focus groups -quantitative methods such as surveys;
including tools such as the EQ 5D. Using NICE as a practical example, NICE provides a range of options including [8] : -Allowing the public and patients to make suggestions for topic areas. This helps to involve the public and patients when not
INTRODUCTION
Health Technology Assessment (HTA) is defined as «a multidisciplinary process that summarizes information about the medical, social, economic and ethical issues related to the use of a health technology in a systematic, transparent, unbiased, robust manner. Its aim is to inform the formulation of safe, effective, health policies that are patient focused and seek to achieve best value» [1] . And to really be that in practice, patients need to be involved, not least to respond to the need for HTA to be patient-focused as outlined in the above definition. The findings that result from appraisal can be very influential in either providing patient access to a new technology or limiting access. The approach that countries take to HTA varies. This editorial draws on selected literature and the example of the National Institute for Health and Clinical Excellence (NICE) in England to explore why patients, and the public more generally, should be involved and how that can be achieved in theory and practice.
WHY INVOLVE THE PUBLIC AND PATIENTS IN HTA?
There are a number of reasons why the public and patients should be involved in HTA.
As NICE acknowledges in their work, patients can [2]: -provide a unique source of evidence on the personal impact of a disease and how technology can make a difference; -identify shortcomings in the published research. Involvement of patients also supports a more transparent approach, making more explicit the normative judgments made in assessing a technology [3] . NICE also acknowledges that given their decisions affect the allocation of public funds, often towards certain groups of patients and given limited funds, away from other groups of patients (or potential patients in the future), that the public more broadly needs representation [4] . Members have a tenure of 3 years, and 10 members change every year. -Inviting the public and patients to contribute to the NICE database on implementation. This means that the public and patients have numerous ways to be involved, which offer lesser or greater commitment for individuals and organizations. The relative success of each approach has not to the knowledge of the author been considered.
WHAT HAPPENS WHEN YOU INVOLVE THE PUBLIC AND PATIENTS?
Final decisions made as a result of HTA are the result of a complex set of factors (i.e. the clinical and economic evidence) and deliberations. In addition, "stakeholder persuasion" has been identified as a factor in NICE recommendations [9] . Disentangling the impact of each factor is difficult, however there is evidence that patient organization submissions can increase the likelihood of a routine rather than restricted use recommendation [10] .
MORE NEEDS TO BE DONE
Few studies are known to the author about the approach to involvement the public and patients in HTA. However, those studies that are available suggest that there may be goodwill to those patients who took part in developing clinical guidelines with NICE, but their perception of influence they had versus others (such as health professionals, health economists and the pharmaceutical industry) was limited [11] . There is also a need to support patient representatives and provide training and information [12] . Overall, more needs to be done to deliver on the potential of involvement with the public and patients [8] . In the authors' view the first step is to ensure that there is a recognition of both the legitimate role for public and patients and the value that they can bring to decision making, and the next to explore what the practical options may be for involvement. Given the myriad number of ways HTA is applied in practice, this should start with a look at the main options in use in other countries, such as the NICE example above, and then to apply judgment as to what is appropriate in the specific context. Lastly there should be ongoing evaluation and adaption to ensure that public and patient involvement is effective and costeffective. This will provide a rich source of insights to adapt and learn over time, to ensure that HTA is truly public and patient-focused.
